More than $50 million in fines has been issued to drug giant Sanofi by France’s Antitrust Authority for what the regulator called a ‘smear campaign’ by the pharmaceutical company against generics drugs. Reports say the Authority found that Sanofi hampered competition by encouraging doctors and pharmacies to provide its brand name blood thinner drug Plavix instead of the generic form. Sanofi said it will appeal the fine. According to reports, Sanofi has looked to up profits since patent protection ended for two of its top-earning drugs, Plavix and blook pressure drug Avapro.
Featured News
Beumer Challenges EU Decision on Vanderlande-Siemens Merger Review
Jul 26, 2026 by
CPI
China Fines Trip.com US$765 Million in Major Antitrust Enforcement Action
Jul 26, 2026 by
CPI
House Judiciary Panel Launches Antitrust Inquiry Into Compass and MRED
Jul 26, 2026 by
CPI
Paramount Delays Warner Bros. Discovery Merger Until Antitrust Case Moves Forward
Jul 26, 2026 by
CPI
Judge Pushes Elite College Financial Aid Antitrust Trial Toward Thanksgiving Finish
Jul 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes